Long-term COVID has been linked to stress, depression and cognitive impairment.

Published Date: 13 Mar 2023

Canada: Long-term COVID-19 associated with psychiatric symptoms and cognitive impairment, research recently published in the journal Brain, Behavior,...

Read Full News

Latest News

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD

6 Psychiatry Headlines You Missed in January 2026

6 Psychiatry Headlines You Missed in January 2026

FDA Examines Generative AI in Psychiatry, With Hans Eriksson, MD, PhD Hans Eriksson, MD, PhD

As mental health AI tools rise, the FDA weighs benefits and risks, emphasizing oversight and performance testing. Eriksson discusses AI in psychiatric care.

Utilizing Alcohol Use Disorder Pharmacotherapy in Hepatology, With Hersh Shroff, MD, MPA Hersh Shroff, MD, MPA

Shroff emphasizes the need to address more than just liver health in patients with alcohol-associated liver disease and reviews trends in AUD pharmacotherapy prescriptions.

The Skin–Brain Axis: Emerging Evidence Transforming Dermatologic Care Lisa A. Swanson, MD, Enzo Berardesca, MD, Mohammad Jafferany, MD

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

Todays Updates

Practice-Changing Ovarian Cancer Updates From SGO 2026

Dr Bradley Corr reviews data on the NRG-GY019 and ROSELLA trials, and discusses their clinical impact on ovarian cancer care.

Data Trends: Heart Failure

Up to 15 million Americans are at risk of heart failure, with mortality rates rising in the US.

Missed Sexual Health Assessment May Limit Clinical Insight

New data show strong links between chronic disease, sexual dysfunction, and loneliness, highlighting missed opportunities for holistic patient evaluation.

US Supreme Court Lets Abortion Pill Mail Delivery Restart for Now

The U.S. Supreme Court temporarily reinstated on Monday a federal rule allowing the abortion pill to be prescribed through telemedicine and dispensed through the mail,...

When Retirement Triggers Risk: Substance Use in Older Adults

Retirement's a critical window: Boredom, pain, and social withdrawal can push older patients toward alcohol or drugs. Doctors should screen, counsel, and refer to tailored services.

Personalized Stimulation Boosts Outcomes in Essential Tremor

Customizable waveforms in a wearable stimulation device were associated with higher responder rates than standard settings in new research.

Adjunctive CBD Improves Neuropsychiatric Symptoms in TSC

Adjunctive cannabidiol improved multiple TSC-associated neuropsychiatric symptoms, including irritability, in a phase 3b/4 study described by investigators as the first to assess these outcomes.

Todays Updates

Practice-Changing Ovarian Cancer Updates From SGO 2026

Dr Bradley Corr reviews data on the NRG-GY019 and ROSELLA trials, and discusses their clinical impact on ovarian cancer care.

Data Trends: Heart Failure

Up to 15 million Americans are at risk of heart failure, with mortality rates rising in the US.

Missed Sexual Health Assessment May Limit Clinical Insight

New data show strong links between chronic disease, sexual dysfunction, and loneliness, highlighting missed opportunities for holistic patient evaluation.

US Supreme Court Lets Abortion Pill Mail Delivery Restart for Now

The U.S. Supreme Court temporarily reinstated on Monday a federal rule allowing the abortion pill to be prescribed through telemedicine and dispensed through the mail,...

When Retirement Triggers Risk: Substance Use in Older Adults

Retirement's a critical window: Boredom, pain, and social withdrawal can push older patients toward alcohol or drugs. Doctors should screen, counsel, and refer to tailored services.

Personalized Stimulation Boosts Outcomes in Essential Tremor

Customizable waveforms in a wearable stimulation device were associated with higher responder rates than standard settings in new research.

Adjunctive CBD Improves Neuropsychiatric Symptoms in TSC

Adjunctive cannabidiol improved multiple TSC-associated neuropsychiatric symptoms, including irritability, in a phase 3b/4 study described by investigators as the first to assess these outcomes.

Latest News

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD

6 Psychiatry Headlines You Missed in January 2026

As mental health AI tools rise, the FDA weighs benefits and risks, emphasizing oversight and performance testing. Eriksson discusses AI in psychiatric care.

Shroff emphasizes the need to address more than just liver health in patients with alcohol-associated liver disease and reviews trends in AUD pharmacotherapy prescriptions.

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

News All Time

Psychiatry in 2025: Year in Review

Psychiatry in 2025: Year in Review

Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA

Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

4 Psychiatry Headlines You Missed in November 2025

4 Psychiatry Headlines You Missed in November 2025

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Single Dose of MM120 (LSD) Shows Lasting Anxiety Reduction in GAD: Phase 2b Results Chelsie Derman

A phase 2b trial finds a single 100 μg dose of MM120 reduced GAD symptoms with benefits lasting 12 weeks, highlighting the promise of psychedelic therapy.

FDA Releases CRL Detailing Safety Concerns for MDMA-Assisted Therapy in PTSD Chelsie Derman

MDMA’s CRL, now available to the public, cites gaps in safety data, selection bias, and limited durability.

Prenatal Opioid Pain Medications Likely Not Linked to Autism or ADHD Risk Chelsie Derman

A study suggests associations between opioids during pregnancy and neurodevelopmental disorders are mainly due to confounding factors, not causal effects.

Atopic Eczema Linked to Suicidal Ideation in Global Study of 30,000 Adults Chelsie Derman

EADV 2025 findings show patients with atopic eczema face greater risks of depression, anxiety, sleep disorders, and stigmatization.

FDA Initiates Acetaminophen Label Change, Leucovorin Approval for Cerebral Folate Deficiency Abigail Brooks, MA

The Agency initiated an acetaminophen label change to reflect evidence of potential harms in pregnant women and an approval of leucovorin for CFD.

Daily Ammoxetine at 40, 60 mg Outperforms Placebo for MDD in Phase 2 Trial Chelsie Derman

A phase 2 trial demonstrated the effectiveness, safety, and tolerability of ammoxetine (40 and 60 mg) in patients with major depressive disorder.

APhA, Coalition of Autism Scientists Cite Insufficient Data to Support Acetaminophen, Autism Link Abigail Brooks, MA

Both organizations defend the use of Tylenol during pregnancy, citing “rigorous” and “reputable” research suggesting it does not cause autism in children.

5 Psychiatry Headlines You Missed in September 2025 Chelsie Derman

This month in review focuses on innovative therapies in psychiatry, including MM120 for anxiety and ammoxetine for depression, as well as providing safety insights.

Recommended News For You

Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma

Study Finds Actionable Mutations in Brain Mets of Breast Cancer Patients

TULSA Is Effective in Long-Term Prostate Cancer Control.

Prostate cancer, rectal exams, Casgevy approved for thalassemia, and two million cancer cases.

Atezolizumab + Cabozantinib Postpones mCRPC Progression.

Discovery of a new biomarker for early detection of bladder cancer in both dogs and humans

The risk of ovarian cancer is not increased by salpingectomy, according to JAMA.

Recommended Articles For You

A Novel Gemcitabine-Releasing Intravesical System for Intermediate-Risk Non-Muscle-Invasive Bladder Cancer 

Liquid Biopsies Unveiling the Future of Precision Cancer Management by 2025 

A Closer Look at the Effects of Sickle Cell on Eyesight 

What Is A Normal Fibrinogen Level, And How Can It Affect Your Health 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Childhood brain tumors develop early in highly specialized nerve cells, research reveals

2.

Electronic Sepsis Alerts; Reducing Plaques in Coronary Arteries

3.

FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.

4.

Obesity-related cancers are more likely in people who are obese in both healthy and unhealthy ways.

5.

Ultrasound imaging of breast cancer tumors offers noninvasive monitoring of treatment effectiveness

1.

Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025

2.

Unlocking the Key to Treating Lymphoma: New Innovations in Cancer Research

3.

Empowering Lung Cancer Diagnosis Through the Synergy of Advanced Technologies and Artificial Intelligence

4.

Exosomes in Cancer: A Novel Frontier for Therapy and Biomarker Discovery

5.

Understanding Acute Intermittent Porphyria: Symptoms, Diagnosis and Treatment

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

2.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I

3.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III

4.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I

5.

Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot